Company Overview
Snapshot
Founded in August 2008 by Yaniv Dolev and Nava Zisapel, Moebius Medical operates with 1–10 employees. The company has completed one funding round with investors RAD BioMed and Pix Vine Capital, and in September 2024, its lead product MM-II received.
Business overview
Moebius Medical is a clinical-stage biotechnology company focused on developing innovative pain-relief treatments for osteoarthritis. Its core product, MM-II, is a patent-protected intra-articular biolubricant injection designed to reduce pain and prevent joint damage in mild to moderate symptomatic knee osteoarthritis. The company operates within the Health Tech & Life Sciences sector, specifically targeting the Pharmaceuticals & Diagnostics market, with a focus on patients suffering from inflammatory diseases.
Strategic signal
In September 2024, Moebius Medical's lead product, MM-II, was granted. This designation, announced in collaboration with Sun Pharma, signals a significant acceleration in the development and regulatory review process for MM-II, highlighting its potential to address an unmet medical need and providing a strong validation of the therapy's clinical promise.
Log in to access full profile ›Company Intelligence Q&A
- What is Moebius Medical's primary focus?
- Moebius Medical is a clinical-stage biotechnology company dedicated to developing novel pain-relief treatments for osteoarthritis.
- What is the status of Moebius Medical's lead product, MM-II?
- MM-II is a patent-protected intra-articular biolubricant injection for the treatment of mild to moderate symptomatic knee osteoarthritis. In September 2024, it received Fast Track Designation for osteoarthritis knee pain.
- When did Moebius Medical receive FDA clearance for its Phase IIb clinical trial?
- In December 2020, the FDA cleared Moebius Medical's Investigational New Drug application to initiate a global multi-center phase IIb clinical trial of MM-II.
- Which companies are collaborating on the development of MM-II?
- In December 2016, Sun Pharma and Moebius Medical entered into an exclusive worldwide licensing deal for the further development of MM-II. Moebius Medical handles preclinical studies and product development through Phase 2, while Sun Pharma manages clinical studies, regulatory submissions, and commercialization.
- What was the outcome of the Phase 2b clinical trial for MM-II?
- In April 2025, Sun Pharma and Moebius Medical announced dual publications regarding MM-II's Phase 2b clinical trial results and its mechanism of action in osteoarthritis and cartilage.